Rhythm-sponsored promotional satellite symposium at ESPE 2026

Advancing breakthrough therapy with setmelanotide for patients living with rare hypothalamic melanocortin-4 receptor (MC4R) pathway diseases
 

During this session, Professor Karine Clément (Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, France), Professor Hanneke van Santen (University Medical Center Utrecht, The Netherlands) and PD Dr Metin Cetiner (University Hospital Essen, Germany) discussed:

• How disruption of the MC4R pathway drives hyperphagia and obesity
• Acquired hypothalamic obesity (aHO): latest data from Phase 3 TRANSCEND trial and real-world evidence
• Bardet-Biedl syndrome (BBS): real-world evidence beyond clinical trials